These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17258358)

  • 1. Kinetics of the immune response following pneumococcal PD conjugate vaccination.
    Schuerman L; Prymula R; Chrobok V; Dieussaert I; Poolman J
    Vaccine; 2007 Mar; 25(11):1953-61. PubMed ID: 17258358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine.
    Silfverdal SA; Hogh B; Bergsaker MR; Skerlikova H; Lommel P; Borys D; Schuerman L
    Pediatr Infect Dis J; 2009 Oct; 28(10):e276-82. PubMed ID: 20118683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
    Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ELISA IgG concentrations and opsonophagocytic activity following pneumococcal protein D conjugate vaccination and relationship to efficacy against acute otitis media.
    Schuerman L; Prymula R; Henckaerts I; Poolman J
    Vaccine; 2007 Mar; 25(11):1962-8. PubMed ID: 17258357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anamnestic immune response in 3- to 4-year-old children previously immunized with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as 2-dose or 3-dose priming and a booster dose in the first year of life.
    Silfverdal SA; Skerlikova H; Zanova M; Papúchová D; Traskine M; Borys D; Schuerman L
    Pediatr Infect Dis J; 2011 Sep; 30(9):e155-63. PubMed ID: 21572373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
    Knuf M; Szenborn L; Moro M; Petit C; Bermal N; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S97-S108. PubMed ID: 19325452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal conjugated vaccine: PHiD-CV.
    Dinleyici EC; Yargic ZA
    Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1063-74. PubMed ID: 19883326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease.
    Vernacchio L; Romero-Steiner S; Martinez JE; MacDonald K; Barnard S; Pilishvili T; Carlone GM; Ambrosino DM; Molrine DC
    J Infect Dis; 2000 Mar; 181(3):1162-6. PubMed ID: 10720547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of 10-valent pneumococcal nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine when administered as catch-up vaccination to children 7 months to 5 years of age.
    Vesikari T; Karvonen A; Korhonen T; Karppa T; Sadeharju K; Fanic A; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2011 Aug; 30(8):e130-41. PubMed ID: 21540760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to primary and booster vaccination with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in Korean infants.
    Kim CH; Kim JS; Cha SH; Kim KN; Kim JD; Lee KY; Kim HM; Kim JH; Hyuk S; Hong JY; Park SE; Kim YK; Kim NH; Fanic A; Borys D; Ruiz-Guiñazù J; Moreira M; Schuerman L; Kim KH
    Pediatr Infect Dis J; 2011 Dec; 30(12):e235-43. PubMed ID: 21817957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines.
    Prymula R; Chlibek R; Splino M; Kaliskova E; Kohl I; Lommel P; Schuerman L
    Vaccine; 2008 Aug; 26(35):4563-70. PubMed ID: 18602724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics of a novel 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine candidate (PHiD-CV). Introduction.
    Dagan R; Frasch C
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S63-5. PubMed ID: 19325448
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants.
    Yu X; Gray B; Chang S; Ward JI; Edwards KM; Nahm MH
    J Infect Dis; 1999 Nov; 180(5):1569-76. PubMed ID: 10515817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dependence of correlations between antibody titres and opsonophagocytosis on pneumococcal serotype and patient morbidity in pre- and post-pneumococcal vaccination states.
    Tarragó D; Aguilar L; Jansen WT; Giménez MJ; Avellón A; Granizo JJ; Casal J
    Clin Microbiol Infect; 2007 Apr; 13(4):369-76. PubMed ID: 17359320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.
    Soininen A; Nohynek H; Lucero M; Jousimies K; Ugpo J; Williams G; Käyhty H;
    Vaccine; 2009 May; 27(20):2680-8. PubMed ID: 19428879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A murine model for the study of immune memory in response to pneumococcal conjugate vaccination.
    Moreno RL; Sampson JS; Romero-Steiner S; Wong B; Johnson SE; Ades E; Carlone GM
    Vaccine; 2004 Aug; 22(23-24):3069-79. PubMed ID: 15297057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-reactivity of antibodies to type 6B and 6A polysaccharides of Streptococcus pneumoniae, evoked by pneumococcal conjugate vaccines, in infants.
    Väkeväinen M; Eklund C; Eskola J; Käyhty H
    J Infect Dis; 2001 Sep; 184(6):789-93. PubMed ID: 11517443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune response to pneumococcal conjugate and polysaccharide vaccines in otitis-prone and otitis-free children.
    Barnett ED; Pelton SI; Cabral HJ; Eavey RD; Allen C; Cunningham MJ; McNamara ER; Klein JO
    Clin Infect Dis; 1999 Jul; 29(1):191-2. PubMed ID: 10433584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.